Natural History Study Protocol in PMM2-CDG (CDG-Ia)
NCT03173300 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2025-11-18
Summary
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)
This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
Conditions
- Phosphomannomutase 2 Deficiency
Sponsors & Collaborators
-
Glycomine, Inc.
lead INDUSTRY
Principal Investigators
-
Chief Medical Officer · Glycomine, Inc.
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-08
- Primary Completion
- 2026-03-31
- Completion
- 2026-03-31
Countries
- United States
- Belgium
- Czechia
- France
- Italy
- Netherlands
- Poland
- Portugal
- Spain
Study Locations
More Related Trials
-
Natural History Studies of Mucopolysaccharidosis III
NCT02037880 ·Status: COMPLETED
-
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
NCT04925960 ·Status: TERMINATED ·Phase: PHASE3
-
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
NCT02435030 ·Status: COMPLETED
-
Mucopolysaccharidosis Type II Natural History
NCT03529786 ·Status: COMPLETED
-
Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2
NCT04470713 ·Status: COMPLETED
-
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
NCT01230801 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
NCT03333447 ·Status: COMPLETED
-
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT02293408 ·Status: TERMINATED
-
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
NCT00053573 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of rhGAA in Patients With Late-Onset Pompe Disease
NCT00250939 ·Status: COMPLETED ·Phase: PHASE2
-
Facioscapulohumeral Dystrophy in Children
NCT02625662 ·Status: COMPLETED
-
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
NCT05705674 ·Status: RECRUITING
-
Natural History Study of Patients With MPS IIIA
NCT02746341 ·Status: COMPLETED
-
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
NCT06666413 ·Status: RECRUITING ·Phase: PHASE4
-
An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression
NCT06079567 ·Status: RECRUITING ·Phase: NA
-
Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA
NCT01733615 ·Status: TERMINATED
-
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
NCT01924026 ·Status: COMPLETED
-
Natural History of Netherton Syndrome
NCT05902663 ·Status: TERMINATED
-
Pompe Disease Registry Protocol
NCT00231400 ·Status: RECRUITING
-
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
NCT01136304 ·Status: COMPLETED
-
A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
NCT02293382 ·Status: COMPLETED
-
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)
NCT01705626 ·Status: COMPLETED
-
Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support
NCT00268944 ·Status: COMPLETED ·Phase: PHASE3
-
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies
NCT03056794 ·Status: RECRUITING
-
GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)
NCT05109793 ·Status: COMPLETED